MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Dr Reddy's Laboratories Ltd-ADR

Suletud

SektorTervishoid

13.15 -0.23

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

13.14

Max

13.23

Põhinäitajad

By Trading Economics

Sissetulek

1.5B

14B

Müük

3.4B

84B

P/E

Sektori keskmine

17.587

73.239

Aktsiakasum

16.936

Dividenditootlus

0.72

Kasumimarginaal

16.795

Töötajad

27,048

EBITDA

2.4B

24B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+37.98% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.72%

3.06%

Turustatistika

By TradingEconomics

Turukapital

8.8B

11B

Eelmine avamishind

13.38

Eelmine sulgemishind

13.15

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

Dr Reddy's Laboratories Ltd-ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. juuni 2024, 13:33 UTC

Omandamised, ülevõtmised, äriostud

Haleon to Sell Nicotine-Quitting Aid Business for $634 Million -- Update

26. juuni 2024, 12:32 UTC

Omandamised, ülevõtmised, äriostud

Haleon to Sell Nicotine-Quitting Aid Business for $634 Million

25. apr 2024, 10:32 UTC

Tulu

Nestle India Reports Rise in Quarterly Profit, Announces JV With Dr. Reddy's Laboratories

23. jaan 2025, 17:46 UTC

Tulu

Dr. Reddy's 3Q Net Attributable to Equity Holders of Parent Company INR14.13B

23. jaan 2025, 17:42 UTC

Tulu

Dr. Reddy's 3Q Rev INR83.59B

5. nov 2024, 11:01 UTC

Tulu

Dr. Reddy's Laboratories 1H Rev INR156.89B Vs. INR136.19B >RDY

5. nov 2024, 11:00 UTC

Tulu

Dr. Reddy's Laboratories 1H Net INR26.47B Vs. Net INR28.825B >RDY

5. nov 2024, 10:57 UTC

Tulu

Dr. Reddy's Laboratories 2Q Net INR12.55B Vs. Net INR14.80B >RDY

5. nov 2024, 10:57 UTC

Tulu

Dr. Reddy's Laboratories 2Q Rev INR80.16B Vs. INR68.80B >RDY

26. juuni 2024, 11:54 UTC

Omandamised, ülevõtmised, äriostud

Haleon: All Other 2024 Guidance Unchanged

26. juuni 2024, 11:54 UTC

Omandamised, ülevõtmised, äriostud

Haleon: Sale Will Dilute 2024 Rev by 0.5%, Adj Oper Pft by 1%

26. juuni 2024, 11:52 UTC

Omandamised, ülevõtmised, äriostud

Haleon: Sale Allow For NRT Exit Outside US, Trims Business Complexity

26. juuni 2024, 11:51 UTC

Omandamised, ülevõtmised, äriostud

Haleon: Deal Expected to Complete Early 4Q

26. juuni 2024, 11:50 UTC

Omandamised, ülevõtmised, äriostud

Haleon: Use of Proceeds Will Be in Line With Capital Allocation Priorities

26. juuni 2024, 11:49 UTC

Omandamised, ülevõtmised, äriostud

Haleon: Deal Structure Upfront Cash GBP458M, GBP42M Performance-Based Payable

26. juuni 2024, 11:48 UTC

Omandamised, ülevõtmised, äriostud

Haleon: Portfolio Includes Nicotinell, Nicabate, Habitrol and Thrive Available in Gum, Lozenge

26. juuni 2024, 11:47 UTC

Omandamised, ülevõtmised, äriostud

Haleon: Deal Worth GBP500M With Additional Proceeds From Inventory Transfer

26. juuni 2024, 11:46 UTC

Omandamised, ülevõtmised, äriostud

Haleon to Sell Non-US Nicotine Replacement Therapy Business to Dr. Reddy's Laboratories

7. mai 2024, 10:56 UTC

Tulu

Dr. Reddy's Laboratories 4Q Net INR13.07B Vs. Net INR9.59B >500124.BY

7. mai 2024, 10:55 UTC

Tulu

Dr. Reddy's Laboratories 4Q Rev INR70.83B Vs. INR62.97B >500124.BY

Võrdlus sarnastega

Hinnamuutus

Dr Reddy's Laboratories Ltd-ADR Prognoos

Hinnasiht

By TipRanks

37.98% tõus

12 kuu keskmine prognoos

Keskmine 18.2 USD  37.98%

Kõrge 19.4 USD

Madal 17 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Dr Reddy's Laboratories Ltd-ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

13.12 / 13.22Toetus ja vastupanu

Lühikene perspektiiv

Neutral Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.